Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Medroxyprogesterone Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 4/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | SHBG | P04278 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 1/20 | 1.00 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Medroxyprogesterone Acetate SCHEMBL13941346 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL3892232 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL14262777 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL4217893 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL4276 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL6835475 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL10080145 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL6563018 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL22761990 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL4277 | 0.98 | NR3C1 (0.96) | NR3C1LMNACYP3A4PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008054598-A9 | PANEL OF BIOMARKERS FOR PREDICTION OF FTI EFFICACY | SCHERING CORP (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008076257-A2 | TREATING CANCER WITH ANTI-IGFLR ANTIBODY 19D12 = SCH 717454 | SCHERING CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076278-A2 | METHODS OF CANCER TREATMENT WITH IGF1R INHIBITORS | SCHERING CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008054598-A2 | PANEL OF BIOMARKERS FOR PREDICTION OF FTI EFFICACY | SCHERING CORPORATION (US) | 2008-05-08 | — | — | WO | disclosed |